This may be due to copious recognition of tumor antigen presented in the context to MHC class I (HY and OVA peptide specific mice) and subsequent TCR-mediated activation of CD8+ cells, while CD4+ T cells are TCR-activated only by antigen presenting cells that carry MHC class II molecules [13,61]. This evidence concerns the gene CD8A and neoplasm.